$0.144
+0.000 (+0.21%)Al cierre
Noticias de SLXN
Eventos de SLXN
Selling Stockholders Plan to Sell 8.81M Ordinary Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 8.81M ordinary shares. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Silexion Therapeutics Doses First Patient with SIL204 in Clinical Trial
Silexion Therapeutics announced that the first patient worldwide has been successfully dosed in its Phase 2/3 clinical trial evaluating the Company's candidate, SIL204, in patients with locally advanced pancreatic cancer, LAPC. The treatment was administered at Tel Aviv Sourasky Medical Center in Israel.
Silexion Therapeutics Reports Positive Findings on SIL204 Study
Silexion Therapeutics announced positive new findings from an ongoing translational study evaluating the cellular uptake and gene-silencing mechanism of its lead candidate, SIL204. The study, part of the Company's translational research program supporting its Phase 2/3 clinical development, demonstrates that SIL204 effectively harnesses naturally occurring circulating lipoproteins to achieve cellular internalization and drive potent, dose-dependent knockdown of mutant KRAS oncogene expression in cancer cells.
Silexion Therapeutics Prices Public Offering at $0.65 per Share
Silexion Therapeutics announced the pricing of a public offering of an aggregate of 3,846,161 of the Company's ordinary shares and series E warrants to purchase up to 3,846,161 ordinary at a combined public offering price of $0.65 per share (or per ordinary share equivalent) and accompanying warrants. The series E warrants will have an exercise price of $0.65 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about August 13, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Silexion Therapeutics Files to Sell Ordinary Shares and Warrants
Silexion Therapeutics files to sell ordinary shares, warrants, no amount given
Artículos relacionados
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.